Clinical trials: Unresectable
Gallbladder Cancer Unresectable
Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
This is a single-arm, multicenter, Phase II clinical trial evaluating the efficacy and safety of Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorilimab (a dual anti-PD-1/CTLA-4 bispecific…
- Trial name
- TRANSFORM-GBC (NCT07310069)
- Testing
- Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
This phase I trial tests the safety, side effects, and best dose of a new drug called nab-paclitaxel/STI-3031 complex (AP160-complex) in treating patients with solid tumors that may have spread from where they first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Melanoma
- Trial name
- NCT05653661
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Sponsor
- Mayo Clinic
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started…
- Trial name
- NCT07050186
- Testing
- Biopsy Procedure, Biospecimen Collection, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Gastric Adenocarcinoma
Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line therapy.
- Trial name
- mSOX (NCT01552980)
- Testing
- S-1 and Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Esophageal Cancer
Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field (PEF) treatment of advanced or unresectable esophageal squamous cell carcinoma patients.
- Trial name
- NCT06756841
- Testing
- PEF treatment
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Energenx Medical LTD.
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Bile Duct Adenocarcinoma
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct…
- Trial name
- NCT06092645
- Testing
- surufatinib plus cadonilimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Colorectal Cancer
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.
- Trial name
- MACBETH (NCT02295930)
- Testing
- folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab
- Where
- 22 sites in Italy
- Volunteers
- 143 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Melanoma
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
Recent progresses have been made in the treatment of metastatic melanoma, nevertheless improved patient survival is still limited because of primary resistance and relapses.
- Trial name
- EXOSOMES (NCT02310451)
- Testing
- blood test
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Bone Cancer, Chondrosarcoma
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery.
- Conditions
- Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma
- Trial name
- NCT01553539
- Testing
- therapeutic angiotensin-(1-7), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Neuroendocrine Tumors
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
The purpose of this study is to determine whether ABI-009 will make advanced, malignant neuroendocrine tumor(s) of the lung, gastrointestinal tract and/or pancreas that cannot be removed by surgery smaller and slow the spread of…
- Trial name
- NCT03670030
- Testing
- ABI-009
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Robert Ramirez
Unresectable Pleural Mesothelioma
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab +…
- Trial name
- eVOLVE-Meso (NCT06097728)
- Testing
- Volrustomig, Pemetrexed, Carboplatin
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 863 people
- Sponsor
- AstraZeneca
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC.
- Trial name
- NCT04394975
- Testing
- Biological : Toripalimab Drug: Axitinib, sunitinib
- Where
- China
- Volunteers
- 421 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Pancreatic Cancer
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and streptozocin administered in 28-day cycles.
- Trial name
- NCT00609765
- Testing
- Avastin, Fluorouracil, Doxorubicin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Post-ATU Study of Nivolumab
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015.
- Trial name
- Post-ATU (NCT03325257)
- Testing
- Routine care
- Where
- 17 sites in France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Liver Cancer
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00589030
- Testing
- brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick," to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00054951
- Testing
- MTC-DOX for Injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- FeRx
HCC - Hepatocellular Carcinoma, Psychological Distress
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depressed.
- Conditions
- HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
- Trial name
- SOLACE (NCT07141056)
- Testing
- Psychological Stress Status
- Where
- 5 sites in China
- Volunteers
- 700 people
- Sponsor
- Guilin Medical University, China